VJOncology is committed to improving our service to you

Share this video  

VJOncology is committed to improving our service to you

BTOG 2020 | NICE rejection of osimertinib: what does this mean for EGFR+ NSCLC in the UK?

The National Institute for Health and Care Excellence (NICE) in the UK has rejected osimetinib for the treatment of EGFR+ non-small cell lung cancer (NSCLC). Here, Riyaz Shah, FRCP, PhD, The Royal Marsden Hospital, London, UK, discusses this decision and what in means for the treatment of this group in the UK. This interview took place at the 18th British Thoracic Oncology Group (BTOG) 2020 congress held in Dublin, UK.

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter